BradleyP.DixonMDFASN

Associate Professor of Pediatrics and Medicine, University of Colorado School of Medicine and Children's Hospital Colorado

Join to view full profile

Dr. Dixon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dixon's full profile

Already have an account?

Office
13123 E 16th Ave
Aurora, CO 80045
Phone+1 720-777-1234

Fax+1 720-777-7200

Summary

Dr. Bradley Dixon is a pediatric nephrologist in Aurora, CO and is affiliated with Children's Hospital Colorado. He received his medical degree from University of Tennessee College of Medicine and has been in practice 19 years. He is experienced in complement-mediated renal diseases including C3 glomerulopathy, membranoproliferative glomerulonephritis, atypical hemolytic uremic syndrome, as well as genetic renal diseases including polycystic kidney diseases.

Education & Training

Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Nephrology, 2003 - 2006
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1999 - 2003
University of Tennessee Health Science Center College of MedicineClass of 1999, MD, Alpha Omega Alpha
College of WoosterBA, Chemistry, Phi Beta Kappa, 1991 - 1995

Certifications & Licensure

CO State Medical License 2017 - 2025
OH State Medical License 1999 - 2019
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Nephrology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Start of enrollment: 2017 Jan 11
Completed
Phase 3
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) Start of enrollment: 2017 Aug 31
Completed
Phase 3
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Start of enrollment: 2018 Jun 12
Completed
Phase 2
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Start of enrollment: 2021 Jul 28
Recruiting
Phase 3
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Start of enrollment: 2021 Nov 17
Recruiting
Phase 3
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Start of enrollment: 2021 Oct 22
Recruiting
Phase 3
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Start of enrollment: 2021 Feb 23
Active, not recruiting
Phase 2
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Start of enrollment: 2018 Jan 22
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

219 citations
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury
Sonata Jodele, Benjamin L. Laskin, Christopher E. Dandoy, Kasiani C. Myers, Javier El-Bietar
Blood Reviews. 2015-05-01
1 citations
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.
Carla M Nester, David L Feldman, Richard Burwick, Spero Cataland, Shruti Chaturvedi
Kidney International. 2024-09-01
95 citations
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Eric Rondeau, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland
Kidney International. 2020-06-01

Journal Articles

Hemolytic Uremic Syndrome
Bradley Dixon, MD, ScienceDirect

Professional Memberships

American Society of Nephrology - ASN
Member
American Society of Pediatric Nephrology (ASPN)
Member
Society for Pediatric Research (SPR)
Member

External Links

Brad Dixon CHCO Faculty Pagehttps://www.childrenscolorado.org/doctors-and-departments/physicians/d/bradley-dixon/
Brad Dixon CU Faculty Pagehttps://www.cudoctors.com/Find_A_Doctor/Profile/27001